Corneal endothelial dysfunction associated with amantadine toxicity

Cornea. 2008 Dec;27(10):1182-5. doi: 10.1097/ICO.0b013e318180e526.

Abstract

Purpose: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine.

Methods: We employed an A-B-A-B single-subject research design that included clinical history, clinical findings, photographic images, and specular microscopic findings of ocular changes.

Results: A 52-year-old woman with Parkinson disease who had taken amantadine for 6 years had bilateral corneal edema for 2 months at baseline. After cessation of amantadine, the edema resolved, and the endothelial cell densities were <or=600/mm. Corneal edema recurred when the administration of amantadine was resumed. Therefore, amantadine was permanently discontinued and the cornea cleared again.

Conclusions: Amantadine can cause reversible corneal edema but can irreversibly reduce the density of endothelial cells.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Amantadine / administration & dosage
  • Amantadine / adverse effects*
  • Amantadine / therapeutic use
  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use
  • Cell Count
  • Corneal Edema / chemically induced*
  • Corneal Edema / physiopathology*
  • Endothelium, Corneal / drug effects*
  • Endothelium, Corneal / pathology
  • Endothelium, Corneal / physiopathology*
  • Female
  • Humans
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Retrospective Studies

Substances

  • Antiparkinson Agents
  • Amantadine